Gilead Sciences, Inc. $GILD Stock: MBL Wealth LLC Raises Holdings

MBL Wealth LLC lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 142.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,496 shares of the biopharmaceutical company’s stock after purchasing an additional 4,402 shares during the quarter. MBL Wealth LLC’s holdings in Gilead Sciences were worth $1,117,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in GILD. BlackRock Inc. purchased a new stake in Gilead Sciences in the 2nd quarter worth approximately $15,393,785,000. Legal & General Group Plc acquired a new stake in shares of Gilead Sciences during the 2nd quarter valued at $1,316,606,000. Deutsche Bank AG acquired a new stake in shares of Gilead Sciences during the 2nd quarter valued at $918,387,000. Jupiter Topco LLC purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at $398,905,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of GILD opened at $156.04 on Friday. The company’s fifty day moving average is $149.10 and its 200-day moving average is $137.85. Gilead Sciences, Inc. has a 12 month low of $114.02 and a 12 month high of $160.51. The firm has a market cap of $193.48 billion, a price-to-earnings ratio of -58.44 and a beta of 0.31. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. Gilead Sciences’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.01 EPS. Equities analysts expect that Gilead Sciences, Inc. will post -0.47 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th were given a $0.82 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.1%. Gilead Sciences’s payout ratio is currently -122.85%.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Inflammation pipeline expanded: Gilead agreed to acquire PepStar Therapeutics’ investigational oral IL-23R inhibitor program, including HCXT-2001, for approximately $1.275 billion in cash. The drug is intended for inflammatory bowel disease and could be developed alone or alongside Gilead’s emvistegrast, strengthening the company’s longer-term growth prospects. Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001
• Positive Sentiment: HIV development update: An ongoing study of a potential weekly oral HIV treatment adds another option to Gilead’s long-acting HIV portfolio. Positive clinical progress could support the company’s dominant HIV franchise and future revenue durability. Gilead’s Weekly HIV Pill Study Adds Long-Acting Firepower
• Positive Sentiment: Oncology collaboration: BioNTech and Gilead will test Gilead’s sacituzumab govitecan with BioNTech’s pumitamig in a global Phase 3 trial for advanced triple-negative breast cancer. The collaboration may improve the commercial potential of Gilead’s oncology platform, although clinical success remains uncertain. BioNTech, Gilead to Test Drug Combination
• Positive Sentiment: Favorable analyst and earnings expectations: TD Cowen reiterated a Buy view, while analysts indicated that Gilead could beat expectations in its upcoming quarterly report. Such forecasts support sentiment, though they are not guarantees of results. Gilead Sciences Receives a Buy from TD Cowen
• Neutral Sentiment: Gilead plans to present new data on rare liver diseases at The Liver Meeting 2026. The presentations could generate future catalysts, but no immediate clinical results were reported. Gilead to Present New Liver-Disease Data
• Negative Sentiment: Legal overhang: Gilead will pay $45 million to settle Texas Medicaid claims alleging unlawful incentives to encourage providers to prescribe its medicines. The financial cost is modest relative to Gilead’s size, but the settlement adds regulatory and reputational risk. Gilead Sciences to Pay $45 Million in Texas Medicaid Settlement

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $123.00 to $126.00 and gave the stock a “sector perform” rating in a research note on Thursday, October 8th. Bank of America lifted their price objective on Gilead Sciences from $168.00 to $172.00 and gave the company a “buy” rating in a research report on Tuesday. Weiss Ratings raised Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Zacks Research downgraded Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 29th. Finally, JPMorgan Chase & Co. upped their target price on Gilead Sciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $159.81.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel O’Day sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $147.90, for a total transaction of $2,218,500.00. Following the completion of the sale, the chief executive officer owned 566,683 shares of the company’s stock, valued at $83,812,415.70. This represents a 2.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the sale, the director directly owned 12,894 shares of the company’s stock, valued at $1,916,306.28. The trade was a 58.26% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 111,000 shares of company stock worth $15,877,860 in the last 90 days. Insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.